NYSE:GKOSMedical Equipment
Glaukos (GKOS) Valuation Check After Strong 2025 Sales Update And Reaffirmed 2026 Revenue Guidance
Glaukos (GKOS) is back in focus after releasing preliminary, unaudited net sales for Q4 and full year 2025 and reaffirming its 2026 revenue guidance at US$600 million to US$620 million.
See our latest analysis for Glaukos.
The reaffirmed 2026 revenue guidance and progress with products like iDose TR come after a 37.94% 3 month share price return, while the 1 year total shareholder return of 23.12% decline shows that longer term momentum has been more mixed.
If Glaukos has you rethinking...